IgA Nephropathy Registration Initiative of High Quality (INSIGHT)

Condition(s) studied

Investigational drug(s) / intervention(s)

No intervention: Registration of all IgAN patients in the First Affiliated Hospital of Sun Yat-sen University and other hospitals which have signed the contract in China.

Study summary

The investigators are registering all biopsy-proven primary IgA nephropathy (IgAN) patients at recruited hospitals and developing a IgAN database in China. Patients will be follow-up every one year, and both baseline and follow-up information will be entered into the registration system. All-cause and cardiovascular mortality and a composite renal outcome of doubling of serum creatinine and end stage renal failure (ESRD, defined as initiation of dialysis or kidney transplantation) of IgAN patients will be compared using the IgAN database.

Eligibility

Primary outcome measure(s)

• All-cause and cardiovascular mortality of IgAN patients — 10 years
• A composite renal outcome of IgAN patients — 10 years
  The composite renal outcome defined as doubling of serum creatinine and ESRD (defined as initiation of dialysis or kidney transplantation).

Trial sites (1)

More Sun Yat-sen University trials in China

Other trials for the same condition